OTC Markets OTCPK - Delayed Quote USD

Ginkgo Bioworks Holdings, Inc. (DNABW)

Compare

0.0091

-0.0002

(-2.15%)

At close: January 10 at 3:08:26 PM EST

Currency in USD All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

217,107.0000

251,455.0000

477,706.0000

313,837.0000

76,657.0000

Cost of Revenue

41,537.0000

54,005.0000

204,216.0000

129,690.0000

15,611.0000

Gross Profit

175,570.0000

197,450.0000

273,490.0000

184,147.0000

61,046.0000

Operating Expense

742,809.0000

965,646.0000

2,482,442.0000

2,012,614.0000

198,073.0000

Operating Income

-567,239.0000

-768,196.0000

-2,208,952.0000

-1,828,467.0000

-137,027.0000

Net Non Operating Interest Income Expense

44,485.0000

57,124.0000

20,156.0000

-1,536.0000

197.0000

Other Income Expense

-128,787.0000

-181,868.0000

67,397.0000

-8,119.0000

11,996.0000

Pretax Income

-651,541.0000

-892,940.0000

-2,121,399.0000

-1,838,122.0000

-124,834.0000

Tax Provision

-352.0000

-71.0000

-15,027.0000

-1,480.0000

1,889.0000

Net Income Common Stockholders

-651,520.0000

-892,869.0000

-2,108,072.0000

-1,888,662.0000

-126,609.0000

Diluted NI Available to Com Stockholders

-651,520.0000

-892,869.0000

-2,108,072.0000

-1,888,662.0000

-126,609.0000

Total Operating Income as Reported

-634,268.0000

-864,406.0000

-2,208,952.0000

-1,828,467.0000

-137,027.0000

Total Expenses

784,346.0000

1,019,651.0000

2,686,658.0000

2,142,304.0000

213,684.0000

Net Income from Continuing & Discontinued Operation

-651,189.0000

-892,869.0000

-2,104,929.0000

-1,830,047.0000

-126,609.0000

Normalized Income

-520,677.5479

-704,512.9779

-2,207,728.3320

-1,900,874.1020

-129,932.6900

Interest Income

44,578.0000

57,217.0000

20,262.0000

837.0000

2,582.0000

Interest Expense

93.0000

106.0000

2,373.0000

2,385.0000

Net Interest Income

44,485.0000

57,124.0000

20,156.0000

-1,536.0000

197.0000

EBIT

-691,890.0000

-892,847.0000

-2,121,293.0000

-1,835,749.0000

-122,449.0000

EBITDA

-630,638.0000

-821,293.0000

-2,076,870.0000

-1,806,673.0000

-108,585.0000

Reconciled Cost of Revenue

41,537.0000

54,005.0000

204,216.0000

129,690.0000

15,611.0000

Reconciled Depreciation

61,252.0000

71,554.0000

44,423.0000

29,076.0000

13,864.0000

Net Income from Continuing Operation Net Minority Interest

-651,189.0000

-892,869.0000

-2,104,929.0000

-1,830,047.0000

-126,609.0000

Total Unusual Items Excluding Goodwill

-130,582.0000

-188,371.0000

103,524.0000

70,898.0000

4,553.0000

Total Unusual Items

-130,582.0000

-188,371.0000

103,524.0000

70,898.0000

4,553.0000

Normalized EBITDA

-500,056.0000

-632,922.0000

-2,180,394.0000

-1,877,571.0000

-113,138.0000

Tax Rate for Calcs

0.0000

0.0003

Tax Effect of Unusual Items

-70.5479

-14.9779

724.6680

70.8980

1,229.3100

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

ALGAE.PA FERMENTALG

0.4375

+6.71%

MMIRF MedMira Inc.

0.0131

0.00%

NRXS NeurAxis, Inc.

2.4900

0.00%

CDIOW Cardio Diagnostics Holdings, Inc.

0.0780

-2.26%

EFTR eFFECTOR Therapeutics, Inc.

0.0002

0.00%

ADAG Adagene Inc.

1.9350

-1.28%

CEROW CERo Therapeutics Holdings, Inc.

0.0171

-12.31%

LVTX LAVA Therapeutics N.V.

0.9758

-5.26%

KTTA Pasithea Therapeutics Corp.

2.5600

-10.49%

FBRX Forte Biosciences, Inc.

17.78

-8.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ginkgo Bioworks Holdings, Inc. (DNABW)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers